Make an enquiry
Refer a patient
HCP Logout

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
Make an enquiry
Refer a patient

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
2021-02-02T00:00:00.000+08:00

Recurrent Prostate Cancer

Recurrent Prostate Cancer
Appl Radiol, volume: Jul/Aug, pages 40-43
Written by Lenzo Nat, BSc BMedSci(Hons) MBBS MSc(Oncol) MMed MHSvMgt EMBA FRACP FAANMS GAICD
Lenzo Nat, BSc BMedSci(Hons) MBBS MSc(Oncol) MMed MHSvMgt EMBA FRACP FAANMS GAICD:::https://www.genesiscare.com/au/our-doctors/prof-nat-lenzo/
 Lim Tee, MBBS, FRANCR
Lim Tee, MBBS, FRANCR:::https://www.genesiscare.com/au/our-doctors/dr-tee-lim/
 Sohi J.S
Sohi J.S:::

Contrary to declining death rates for many common cancers, prostate cancer deaths are rising, with an increase of 5 percent from 2019 to 2020.1 Although most primary prostate cancer cases can be managed with radiotherapy or radical prostatectomy, 40 percent of men treated for this cancer will have disease relapse,2 with castration-resistant prostate cancer accounting for most deaths.3 68Ga PSMA-11 PET/CT suggests better sensitivity to low levels of PSA,4 and the ability to identify the location of disease recurrence after radical prostatectomy in half of the patients with a PSA level between 0.5 and 1 ng/ml,5,6 as demonstrated in this case study.

Disclaimer:

This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.